The FDA has signed off on emergency use of PerkinElmer’s (PKI +1.5%) Anti-SARS-CoV-2 ELISA (IgG) blood test developed at subsidiary EUROIMMUN.
The company says the test has 100% sensitivity
(correctly identifying true positives) and 99% specificity (correctly
identifying true negatives) after 21 days following the onset of
COVID-19 symptoms.
https://seekingalpha.com/news/3569114-fda-oks-emergency-use-of-perkinelmer-covidminus-19-blood-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.